Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

t December 31, 2009. Of the costs incurred in relation to the OGX-011 development plan, $2.8 million is receivable from Teva as of March 31, 2010. For 2010, we anticipate that we will incur operating expenses of between $30 million and $32 million, an increase from prior guidance which reflects additional manufacturing responsibilities for the Company under the OGX-011 development plan. These additional manufacturing costs are reimbursable from Teva and consequently there will be a corresponding increase in revenue for 2010. We continue to anticipate ending the year with cash, cash equivalents, short-term investments, and amounts receivable of between $29 million and $31 million.

The Company believes that its cash, cash equivalents, short-term investments and amounts receivable will be sufficient to fund its currently planned operations into 2012 and expect that both Phase III prostate cancer trials will be fully accrued by this time. The Company had 6,375,461 shares outstanding as at May 5, 2010.

"So far in 2010 we have advanced towards achieving key objectives for both OGX-011 and OGX-427 and have also added substantial biopharmaceutical experience to our Board of Directors," said Scott Cormack, president and chief executive officer of OncoGenex. "We remain on target to initiate the OGX-011 Phase III trial evaluating OGX-011 with docetaxel retreatment as second-line therapy in castrate-resistant prostate cancer ("CRPC") in the second quarter of 2010, while the Phase III trial evaluating OGX-011 with first-line docetaxel treatment in CRPC, the Phase II trial evaluating OGX-427 as a monotherapy in CRPC, and the Phase III trial evaluating OGX-011 with first-line chemotherapy in non-small cell lung
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Reprints Desk, Inc., a Research Solutions (OTCQB: ... scientific, technical and medical (STM) content, today announced a ... Southeastern Research Libraries (ASERL) . ASERL is ... southeastern states. Founded in 1956, ASERL has a long ... the continually changing needs of its member libraries. ...
(Date:5/5/2015)... USA (PRWEB) May 05, 2015 A ... covering a wide range of key photonics technologies – ... global competitiveness of U.S. industry. To help the community ... on 12 May on the proposed changes to ... commodities covered by International Traffic in Arms Regulations (ITAR). ...
(Date:5/5/2015)... May 05, 2015 Research and Markets ... of the "Clinical Laboratory, Molecular Diagnostics and ... to 2019 - Europe Version" report to ... in the area of molecular diagnostics and pharmacogenics ... evolving world market that is moving out of ...
(Date:5/5/2015)... , May 5, 2015   Tocagen Inc. ... David R. Parkinson , M.D., a venture ... appointed to the board of directors of Tocagen. ... experience in oncology clinical development, including leading clinical ... global approvals of the cancer therapeutics Gleevec®, Femara®, ...
Breaking Biology Technology:Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4
... VIRxSYS Corporation, a,privately held company developing gene ... a privately-owned biotechnology company,focused on the manufacture and ... agreed to settle the pending litigation between,the two ... counterclaims,asserted in the lawsuit, which has been pending ...
... to ... Meet Growing Global Demand, WILMINGTON, Del., ... C. Fanandakis group vice president - DuPont Applied,BioSciences. In this ... commercialize a range of bio-based,products and technologies to meet growing ...
... (Nasdaq and MTAX: CTIC) today announced that the ... granted authorization to,publish the Italian listing prospectus, according ... Article 56 of the CONSOB Regulation no. 11971/99,relating ... than 10% of,the shares of common stock currently ...
Cached Biology Technology:VIRxSYS and Lentigen Announce Litigation Settlement 2DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences 2Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus 2Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus 3
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... June 27th, 2010 The Elsevier Foundation, TWAS and ... women scientists from Africa, the Middle East, Asia, Latin ... announcement was made at the Third World Organization for ... Conference, Women Scientists in a Changing World, hosted by ...
... tropical forests so biologically rich? Smithsonian researchers have new ... mysteries lies underground, according to a study published in the ... that tree seedlings do not grow and survive well under ... said Scott Mangan, postdoctoral fellow at the University of WisconsinMilwaukee ...
... The July issue of GEOLOGY presents studies ... river dataset examining whether the sedimentological record can help document ... development of the NW British continental margin, how rivers react ... GSA TODAY looks at individual mineral grains as ...
Cached Biology News:12 women scientists announced as winners of Elsevier Foundation TWOWS Awards 2Biodiversity's holy grail is in the soil 2July 2010 Geology and GSA Today highlights 2July 2010 Geology and GSA Today highlights 3July 2010 Geology and GSA Today highlights 4July 2010 Geology and GSA Today highlights 5July 2010 Geology and GSA Today highlights 6July 2010 Geology and GSA Today highlights 7July 2010 Geology and GSA Today highlights 8July 2010 Geology and GSA Today highlights 9July 2010 Geology and GSA Today highlights 10July 2010 Geology and GSA Today highlights 11July 2010 Geology and GSA Today highlights 12July 2010 Geology and GSA Today highlights 13July 2010 Geology and GSA Today highlights 14July 2010 Geology and GSA Today highlights 15